相关实验视频

Updated: May 7, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

穆拉诺研究:对复发性/耐药性CLL患者的VenR的最终分析和再治疗/交叉子研究结果

Arnon P Kater¹, Rosemary Anne Harrup², Thomas J Kipps³

¹Amsterdam University Medical Centers, Amsterdam, Netherlands.

|February 26, 2025

概括

在最终的MURANO试验分析中,固定时间的venetoclax-rituximab (VenR) 与bendamustine-rituximab (BR) 相比,在复发性/逆转性慢性淋巴细胞白血病 (CLL) 患者中显著改善了无进展生存率和整体生存率.

科学领域:

血液学血液学血液学
临床瘤学临床瘤学
药理学药理学是指药理学的学科.

背景情况:

复发性/耐药性慢性淋巴细胞白血病 (CLL) 是一个重大的治疗挑战.
之前的研究表明,venetoclax-rituximab (VenR) 治疗可能有好处.

研究的目的:

报告第3期MURANO试验的最终分析,评估固定持续时间的VenR与复发性/耐药性CLL中的bendamustine-rituximab (BR) 相比.
评估长期无进展生存 (PFS) 和整体生存 (OS) 的结果.

主要方法:

随机,开放标签,第三阶段试验 (MURANO) 将固定持续时间的VenR (2年) 与BR (6个月) 进行比较.
患有复发性/耐药性CLL的患者被随机分组 (n=389).
一项副研究包括患有进展性疾病的患者接受VenR再治疗或交叉治疗.

主要成果:

与VenR的PFS中位数为54.7个月,与BR的PFS中位数为17.0个月.
7年的PFS为VenR的23.0%,7年的OS为VenR的69.6%,与BR的51.0%相比.
在治疗结束时无法检测到的最小残留疾病 (uMRD) 与EOT的显著更长的PFS相关.

结论:

与BR相比,固定持续时间的VenR在复发性/耐药性CLL中显示出更高的长期疗效和生存结果.
在治疗后实现 uMRD 与持续缓解有关.
这些发现支持VenR作为这种患者群体的首选治疗选择.

更多相关视频

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Varicose Veins II: Diagnostic Studies and Interprofessional Care

Varicose Veins II: Diagnostic Studies and Interprofessional Care

Varicose veins, or varicosities, develop when the valves in the veins, which control blood flow, weaken or damage. It causes blood to pool and the veins to enlarge. Understanding the clinical manifestations, diagnostic approaches, and management options for varicose veins is crucial for effective treatment and relief.Clinical manifestationsClinical manifestations of varicose veins include a heavy, achy feeling or pain after prolonged standing or sitting. This discomfort can often be relieved by...